journal article·2018-11-12Open access

Paclitaxel-loaded TPGS enriched self-emulsifying carrier causes apoptosis by modulating survivin expression and inhibits tumour growth in syngeneic mammary tumours

Jaya Gopal Meher, Shivani Dixit, Darshad Khan Pathan, Yuvraj Singh, Hardik Chandasana, Vivek K. Pawar, Mani Sharma, Rabi Sankar Bhatta, Rituraj Konwar, Prashant Kesharwani, Manish K. Chourasia

Abstract

M cell cycle arrest, apoptosis, mitochondrial membrane potential disruption and ROS production was exhibited by PTX-SEDDS in comparison to Taxol. Up-regulation of Bax, p21, cleaved-caspase 3, -caspase 9 and down-regulation of Bcl2 and survivin suggested apoptosis via intrinsic pathways. Pharmacokinetic study showed approximately 4-folds higher oral bioavailability of PTX-SEDDS than Taxol. Significant reduction in tumour volume and weight was observed in syngeneic mammary tumour in SD rats. Tumour histopathology and TUNEL assay showed apoptosis in tumour tissue. PTX-SEDDS caused low lung metastasis, and was safe and stable. Conclusively, PTX-SEDDS could be suitable option for oral delivery of PTX.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · 3D Printing in Biomedical Research · Innovative Microfluidic and Catalytic Techniques Innovation

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Pharmaceutics and Pharmacokinetics Division, CSIR-Central Drug Research Institute

Endocrinology Division, CSIR-Central Drug Research Institute

Funding

Department of Biotechnology, Government of India

References (28)

Show source-provided references
1. 10.1016/S0378-5173(98)00188-410.1016/S0378-5173(98)00188-4 ↗
2. Price KS, Castells MC. Taxol reactions. Allergy Asthma Proc. 2002;23:205–208.
3. 10.1016/j.ijpharm.2005.01.01110.1016/j.ijpharm.2005.01.011 ↗
4. Terwogt JMM, Malingre MM, Beijnen JH, et al. Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clinical Cancer Research 1999;5:3379–3384.
5. 10.1021/mp060121r10.1021/mp060121r ↗
6. 10.1016/S0168-3659(02)00025-110.1016/S0168-3659(02)00025-1 ↗
7. 10.1016/j.ejps.2013.02.00610.1016/j.ejps.2013.02.006 ↗
8. 10.1016/j.jconrel.2014.10.01010.1016/j.jconrel.2014.10.010 ↗
9. 10.1016/j.ijpharm.2009.08.03510.1016/j.ijpharm.2009.08.035 ↗
10. 10.3109/10837450.2013.79517010.3109/10837450.2013.795170 ↗
11. Yang XH, Sladek TL, Liu X, et al. Reconstitution of caspase 3 sensitizes MCF-7 breast cancer cells to doxorubicin- and etoposide-induced apoptosis. Cancer Res. 2001;61:348–354.
12. 10.1016/j.bbagen.2016.07.00110.1016/j.bbagen.2016.07.001 ↗
13. 10.1039/C6RA02663J10.1039/C6RA02663J ↗
14. 10.2165/00003088-199630030-0000110.2165/00003088-199630030-00001 ↗
15. 10.1016/0378-5173(94)00222-Q10.1016/0378-5173(94)00222-Q ↗
16. 10.1016/j.carbpol.2013.03.07610.1016/j.carbpol.2013.03.076 ↗
17. 10.1016/j.jconrel.2015.06.01910.1016/j.jconrel.2015.06.019 ↗
18. 10.1016/j.ijpharm.2014.05.03910.1016/j.ijpharm.2014.05.039 ↗
19. 10.1091/mbc.e14-04-091610.1091/mbc.e14-04-0916 ↗
20. 10.1038/nrc96810.1038/nrc968 ↗
21. 10.1016/j.biomaterials.2012.08.00710.1016/j.biomaterials.2012.08.007 ↗
22. 10.1016/j.ctrv.2008.04.00310.1016/j.ctrv.2008.04.003 ↗
23. 10.1016/j.biomaterials.2012.03.04610.1016/j.biomaterials.2012.03.046 ↗
24. 10.1016/j.bcp.2014.02.00310.1016/j.bcp.2014.02.003 ↗
25. 10.1054/bjoc.2001.211810.1054/bjoc.2001.2118 ↗
26. 10.1007/s10616-008-9173-910.1007/s10616-008-9173-9 ↗
27. 10.1016/j.physbeh.2013.05.02610.1016/j.physbeh.2013.05.026 ↗
28. 10.1016/j.jconrel.2014.03.00910.1016/j.jconrel.2014.03.009 ↗